DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and...
Richard Lehman, MD does not let moss grow under his feet. As you will hear in this episode, he is involved in the whole...
Yuri is a forward-thinking entrepreneur and thought leader who has a true passion for community and global impact projects. He has served in a...
